Pegvaliase for the treatment of hyperphenylalaninaemia in adults with phenylketonuria first line
|
|
- Ambrose Shon Peters
- 6 years ago
- Views:
Transcription
1 May 2016 Horizon Scanning Research & Intelligence Centre Pegvaliase for the treatment of hyperphenylalaninaemia in adults with phenylketonuria first line LAY SUMMARY This briefing is based on information available at the time of research and a limited literature search. It is not intended to be a definitive statement on the safety, efficacy or effectiveness of the health technology covered and should not be used for commercial purposes or commissioning without additional information. Phenylketonuria (PKU) is an inherited disorder of protein metabolism that causes a problem with the phenylalanine hydroxylase enzyme. This enzyme is responsible for breaking down the amino acid phenylalanine, a chemical in protein from food, so that in PKU the amount of phenylalanine in the blood increases. Hyperphenylalaninaemia is when the levels of phenylalanine in the blood are too high. If untreated, hyperphenylalaninaemia can cause damage to the brain which can cause severe mental disability, seizures and tremors. In addition, it may lead to psychological, social and behavioural problems, and lead to depression, anxiety, phobias and low self-esteem. Pegvaliase is a new drug which is injected into the skin daily to treat hyperphenylalaninaemia in adult patients with PKU. PKU is currently treated by adopting a protein restricted diet and taking dietary supplements, pegvaliase could potentially allow patients to relax these dietary restrictions. NIHR HSRIC ID: 5020 This briefing presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the author and not necessarily those of the NHS, the NIHR or the Department of Health. NIHR Horizon Scanning Research & Intelligence Centre, University of Birmingham. nihrhsc@contacts.bham.ac.uk Web:
2 TARGET GROUP Phenylketonuria (PKU): hyperphenylalaninaemia; adults first line; adjunct to the PKU diet a. TECHNOLOGY DESCRIPTION Pegvaliase (BMN 165; PEG PAL; pegylated phenylalanine ammonia lyase; ravpal-peg) is a pegylated recombinant phenylalanine ammonia lyase intended for the treatment of hyperphenylalaninaemia in adults with PKU. Pegvaliase is self-administered by subcutaneous (SC) injection for an induction period (4 weeks) at a fixed dose of 2.5 mg/week. This is followed by a titration period (week 5 up to week 32) where pegvaliase is administered by SC injection at increasing doses up to 20mg or 40mg/day. A maintenance regimen is then used in order to safely achieve the target phenylalanine level for the individual patient, this is administered for a further 4 weeks b. Pegvaliase does not currently have Marketing Authorisation in the EU for any indication. INNOVATION and/or ADVANTAGES If licensed, pegvaliase will offer an additional treatment option for adult PKU patients with hyperphenylalaninaemia b. Expert opinion suggests that there is a great desire amongst patients and families for a treatment which allows relaxation of the PKU diet a. DEVELOPER BioMarin Europe Limited. AVAILABILITY, LAUNCH OR MARKETING Pegvaliase is in phase III clinical trials. PATIENT GROUP BACKGROUND PKU is a rare inherited disorder of protein metabolism, where there is a deficiency in the enzyme phenylalanine hydroxylase (PAH). PAH catalyses the conversion of the amino acid phenylalanine to tyrosine. PAH deficiency prevents normal metabolism of phenylalanine, causing it to accumulate in the blood. PKU is an autosomal recessive disorder; most forms are caused by mutations in the PAH gene on chromosome 12q All babies born in the UK are routinely screened for high phenylalanine levels in the first week of life 1. High levels of phenylalanine can damage the brain which, if not recognised and managed can cause severe mental disability, reduced IQ, seizures and tremors, impaired a Expert personal opinion. b Company provided information. 2
3 executive function, psychological and behavioural issues, social difficulties and epilepsy 2,3. Untreated PKU is associated with an abnormal phenotype which includes growth failure, poor skin pigmentation, microcephaly, seizures, global developmental delay and severe intellectual impairment 1. However, since the introduction of newborn screening programmes and early dietary intervention, severe mental retardation associated with untreated classical PAH deficiency can be prevented 1,4. Over time, subtle intellectual and neuropsychiatric issues may manifest even with treatment 4. Common reported conditions in adult patients with PKU include: depression, anxiety disorders, phobias and low self-esteem 2. Current management of PKU involves meticulous management of the diet. For a significant number of patients the restrictions of the diet impact greatly on their day to day life c. It can be a burden for parents and carers to administer and supervise, particularly as children become older and more independent c. As the child grows and they become more independent, the social impact increases due to the limitations on lifestyle. Being on a medical diet creates differences at school and college, occasionally leading to bullying, which young patients find difficult to manage c. The planning and organisation that goes into food can preclude spontaneous enjoyment of meals, holidays and family occasions, and can increase the risk of eating disordered behaviour c. In some cases the difficulties result in reduced adherence to dietary treatment with higher phenylalanine levels, and this can negatively impact on cognition and mood long-term c. Current recommendations are that individuals with PKU continue this diet lifelong although many adults with PKU struggle to adhere strictly to this recommendation, and some opt to discontinue the PKU diet completely c. Reported difficulties in adult patients include impairment of executive function and anxiety c. Other individuals with variable/poor adherence have developed problems secondary to nutritional, e.g. vitamin B12, deficiencies c. Some individuals with PKU find the supplements and low protein foods unpalatable c. The supplements used in the PKU diet are strong tasting c. An alternative to the liquid supplement involves taking over 100 tablets a day d. Regular home blood monitoring of phenylalanine levels can also be a major burden of the disorder c. Monitoring of blood phenylalanine levels is made difficult by the delay in receiving results, and it is suggested that this can currently take approximately 2-3 days d. This is of particular concern as phenylalanine blood levels are elevated during illness d. NHS or GOVERNMENT PRIORITY AREA This topic is relevant to the following Department of Health policy areas: NHS England. 2013/14 NHS Standard Contract for Paediatric Neurosciences: Neurology. E09/S/b. NHS England. July Clinical Commissioning Policy: The use of sapropterin in children with phenylketonuria. E06/P/a. CLINICAL NEED and BURDEN OF DISEASE The incidence of positive screening tests for PKU was 1 in 10,998 live births in , with an overall incidence of 1 in 8,600 from Not all screen positives will prove to c Expert personal opinion. d Patient group personal communication. 3
4 have PKU, but according to expert opinion, the vast majority do e. Carriage frequency of dysfunctional alleles is about 1 in The population likely to be eligible to receive pegvaliase could not easily be estimated from routine available published sources. PATIENT PATHWAY RELEVANT GUIDANCE NICE Guidance No relevant guidance. Other Guidance The National Society for Phenylketonuria. Management of Phenylketonuria American College of Medical Genetics and Genomics. Phenylalanine hydroxylase deficiency: diagnosis and management guideline CURRENT TREATMENT OPTIONS PKU can be successfully treated by strict compliance with a low-protein diet and dietary supplements, such as low protein medical foods, amino acid, vitamin and mineral supplements (provided on prescription) 1. Dietary supplements contain essential nutrients and amino acids that are absent in a low-protein diet. This treatment is very effective and with good control of phenylalanine levels, the majority of individuals with PKU would be expected to achieve a normal IQ, allowing them to access education, employment and relationships independently. As the PKU diet is started immediately upon diagnosis in the neonatal period, for many individuals they grow up with this diet, are used to it, and incorporate it well into daily life. However, data suggests that blood phenylalanine concentration cannot always be maintained below the recommend value. In children younger than age 4 years, almost 30% of blood phenylalanine concentrations were greater than the recommended maximum value, but in year olds, this proportion rises to 80%, despite older children and adolescents being on a more relaxed diet 8. EFFICACY and SAFETY Trial NCT , , Prism301; pegvaliase; phase III. Sponsor BioMarin Pharmaceutical NCT , , Prism302; pegvaliase vs placebo; phase III. BioMarin Pharmaceutical NCT , , Prism303; pegvaliase; phase III extension. BioMarin Pharmaceutical Status Complete but unpublished. Ongoing. Ongoing. Source of information Trial registry 9 ; manufacturer. Trial registry 10 ; manufacturer 11. Trial registry 12 ; manufacturer. Location USA. USA. USA. e Expert personal opinion. 4
5 Design Randomised. Randomised, placebocontrolled. Participants n=300; aged yrs; n=250 (planned); pts who PKU with blood have completed a prior phenylalanine pegvaliase study (PAL-003 concentration >600µmol/L or ); after Part 1 of at screening or average the study pts with blood blood phenylalanine phenylalanine concentration of >600 concentration reduction µmol/l over the past 6 20% from baseline levels months. in study are eligible for participation in Part 2; pts unable to achieve the 20% blood phenylalanine reduction are eligible for participation in Part 4. Schedule Follow-up Primary outcomes Randomised to pegvaliase 20mg/day; or pegvaliase 40mg/day; both as selfadministered SC injections. Both arms receive a dose of 2.5mg/wk for 4 wks (induction period) followed by a titration period (wk 5 up to wk 42) in which increased doses (20mg/day or 40mg/day) are administered. A maintenance dose period of at least 2 weeks follows where the pt receives either pegvaliase 20mg/day or 40mg/day. Active treatment for up to 36 wks. Safety and tolerability (assessment of vital signs, physical examination, electrocardiograms (ECGs), adverse effects (AEs), concomitant medications and laboratory In Part 1 (up to 13 wks), pts receive pegvaliase SC at the same dosage as allocated in their previous study. In Part 2 (8 wks) pts are randomised to either continue their Part 1 pegvaliase dose (20mg/day or 40mg/day) or receive matching placebo for 8 wks. In Part 3 (6 wks), subjects who completed and received pegvaliase in Part 2 will continue to receive open-label pegvaliase at Part 2 dosage. Subjects will temporarily halt dosing in wk 6 before entering Part 4. All other subjects will be enrolled in Part 4. Part 4 (up to 190 wks) is an open-label extension period. Pts on a dose of 20mg/day in part 2 will continue with this dose in wk 1 and increase to 40mg/day at wk 2. All other pts will be treated at a dose of 40mg/day unless AEs previously prevented dosing at 20 or 40mg/day. Active treatment for up to 217 wks. Change in blood phenylalanine concentration from Part 2 baseline to Part 2 wk 8. Non-randomised, uncontrolled. n= 100 (planned); aged yrs; pts in Part 1 of study and meet criteria for Part 2 of ; pts who are concurrently administered study drug (pegvaliase and/or placebo) in Part 2 of study Patients receive pegvaliase 20mg/day SC; or pegvaliase 40mg/day SC; or placebo SC as allocated in Part 2 of study Changes in executive function (measured by Cambridge Neuropsychological Test Automated Battery [CANTAB]). 5
6 tests f ). Secondary outcomes Blood phenylalanine concentration; percentage of daily recommended intake for age of natural protein intake; dietary protein intake; Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS) score (investigator rated inattentive subscale score, total score, and hyperactivity/impulsivity subscale score); Profile of Mood States (POMS) scores (observer rated and subject rated); pharmacokinetics. Change from Part 2 baseline to Part 2 wk 8 in cognitive and mood symptoms: ADHD Rating Scale-IV (ADHD-RS IV); PKU-specific POMS; PKU POMS total mood disturbance score. AEs; pharmacokinetics; protein intake reported in diet diary. Key results Not reported. The pegvaliase group maintained mean blood phenylalanine levels at 527.2μmol/L compared to baseline of 503.9μmol/L,; placebo group blood levels increased to μmol/L compared to baseline of 536.0μmol/L. 62% improvement in blood phenylalanine compared to placebo. Adverse effects (AEs) Expected reporting date Not reported. The company have not stated an expected reporting date. No pts discontinued study drug due to AEs and pegvaliase was generally well tolerated compared to placebo. Pegvaliase treated patients had more hypersensitivity AEs (39%) than the placebo group (14%). For pegvaliase vs placebo, respectively, the most frequent AEs were: arthralgia (14% vs 10%), headache (12% vs 24%), and fatigue (11% vs 10%). Study completion date reported as November Study completion date reported as April Trial NCT , ; pegvaliase; phase II. Sponsor BioMarin Pharmaceutical Status Complete but unpublished. NCT , PAL-002; pegvaliase; phase II. BioMarin Pharmaceutical Complete but unpublished. NCT , PAL-003; pegvaliase; phase II. BioMarin Pharmaceutical Ongoing. f Chemistry, haematology, and urinalysis tests. 6
7 Source of Trial registry 13. Trial registry 14. Trial registry 15. information Location USA. USA. USA. Design Randomised. Non-randomised, uncontrolled. Non-randomised, uncontrolled. Participants n=24; aged yrs; PKU with blood phenylalanine concentration of 600µmol/L at screening, average blood phenylalanine concentration of 600µmol/L over past 6 months. n=40; aged yrs; blood phenylalanine concentration 600μmol/L at screening (average 600μmol/L over the previous 3 yrs). n=50 (planned); aged yrs; pts who have completed participation in previous pegvaliase studies. Schedule Randomised to pegvaliase 4-8 wks induction at 2.5mg, followed by titration ( 4 wks) to find efficacious dose, followed by daily maintenance at that dose, all administered SC from 1-5 times per wk (2.5mg-375mg); or 8mg single bolus dose, followed by minimum 3-wk break, then titration ( 4 wks) to maintenance dose, all administered SC from 1-5 times per wk (2.5mg-375mg). Follow-up Active treatment for 24 weeks. Follow-up not reported. Primary outcomes Secondary outcomes Expected reporting date Phenylalanine plasma levels. Safety assessments (assessment of injection sites, vital signs and AEs.); safety tests g at baseline and at completion of the study; immunogenicity. No quality of life measurement included in trial outcomes. The company have not stated an expected reporting date. Pts receive pegvaliase SC at dose of 0.001, 0.003, 0.01, 0.03, or 0.1mg/kg on day 1; doses were increased progressively up to 0.1mg/kg. Treatment period and follow-up not reported. Blood phenylalanine concentrations AEs and clinically significant changes in vital signs and laboratory test results; antibody response; pharmacokinetics. No quality of life measurement included in trial outcomes. The company have not stated an expected reporting date. Pts receive pegvaliase SC at dose of 0.001, 0.003, 0.01, 0.03, or 0.1mg/kg on day 1; doses were increased progressively but did not exceed the upper limit of 5.0mg/kg per wk or 375mg/wk. Active treatment 392 wks. Follow-up not reported. Blood phenylalanine concentrations (3 days postdose). AEs and clinically significant changes in vital signs; antibody response; pharmacokinetics; safety based on clinically significant changes in laboratory test results. No quality of life measurement included in trial outcomes. Study completion date reported as August g Chemistry, haematology and urinalysis monthly clinical laboratory tests. Physical examination every other month, along with pregnancy test, ECG and chest x-ray. Patients assessed for AEs every time they are seen by clinical personnel. 7
8 ESTIMATED COST and IMPACT COST The cost of pegvaliase is not yet known. IMPACT SPECULATIVE Impact on Patients and Carers Reduced mortality/increased length of survival Other: due to dietary treatment patients are expected to have a normal life span so pegvaliase will not impact survival or mortality h. Reduced symptoms or disability: pegvaliase may allow patients to follow a less strict version of the diet h. This will be of particular importance for those who struggle with the PKU diet. Reducing the dietary restriction on how much, and what, can be included in the diet will have a positive psychosocial impact as well as a positive impact on neurocognitive outcomes h. If there is improved compliance and better control of phenylalanine levels patients will have better quality of life and outcome in terms of anxiety, better job performance, relationships etc h. No impact identified Physical adverse effects from the current dietary treatment for PKU (assuming good metabolic control is achieved) are minimal and mainly centre around palatability and gastrointestinal (in)tolerance h. Pegvaliase has a greater side effect profile with arthralgia, injection site reactions and rash reported. It remains to be seen how well patients would tolerate these adverse effects long-term h. Impact on Health and Social Care Services Increased use of existing services: potential increase in number of adult patients receiving active treatment h. Decreased use of existing services. Potential increase in lab monitoring requirements h. Re-organisation of existing services: the current metabolic centres that already take care of these patients will be involved h. The pegvaliase treatment would be expected to have a similar resource need as current treatment; but with more emphasis on the role of the nurse specialist rather than the dietitian and dietetic assistant h. Need for new services h Expert personal opinion. 8
9 Training would need to be given to parents/patients on the administration of the pegvaliase injection this would not be expected to be complex but would require nurse specialist time i. Other None identified Impact on Costs and Other Resource Use Increased drug treatment costs Other increase in costs Other Reduced drug treatment costs Other reduction in costs None identified Other Issues Clinical uncertainty or other research question identified: unclear place in treatment as trials in adults, (of which approximately half may be off diet anyway due to patient choice i ) while management starts from newborn screening i. Research needs to explore if first line is the most suitable place in treatment i. The main patient group adhering to strict diet is the paediatric population i ; research is needed into the use of this treatment (including adverse events and tolerance of regular SC injections) in children and adolescents given that the greatest demand for use of pegvaliase is likely to come from parents and carers of children and adolescents with PKU i. None identified Research is required on the levels of phenylalanine in the blood after treatment with pegvaliase and whether this drug is given alone or in combination with the restricted diet i. Future research should focus on symptoms and how this treatment may affect symptoms j. Trials should closely monitor the diet of the participants in order to record any changes in dietary restriction j. Research should consider the impact on quality of life (perhaps using the phenylketonuria quality of life (PKU-QOL) questionnaires) i,16, the impact on common conditions reported in adult patients such as depression and anxiety, and the long term impact on cognitive/psychological outcomes. A key area for research is the potential use of pegvaliase in PKU mothers during pregnancy (known as maternal PKU) i,j. Kuvan (sapropterin) is used off-label in maternal PKU patients i,j. Research is needed into whether pegvaliase can be used in this way j. i Expert personal opinion. j Patient group personal communication. 9
10 REFERENCES 1 Williams RA, Mamotte CDS and Burnett JR. Phenylketonuria: an inborn error of phenylalanine metabolism. Clinical Biochemistry Review 2008; 29(1): NHS Choices. Phenylketonuria. Accessed 13 April Hagedorn TS, van Berkel P, Hammerschmidt G et al. Requirement for a minimum standard of care for phenylketonuria: the patient s perspective. Orphanet Journal of Rare Disease 2013; 8(191). 4 Vockley J, Andersson HC, Antshel KM et al. Phenylalanine hydroxylase deficiency: diagnosis and management guideline. Genetics in Medicine 2014;16(2): Public Health England. Data Collection and Performance Analysis Report: Newborn blood spot screening in the UK 2014/15. London: PHE; March Patient.info. Phenylketonuria. Accessed 6 April The National Society for Phenylketonuria. Management of Phenylketonuria. NSPKU; Lancashire. July Walter JH, White FJ, Hall SK et al. How practical are recommendations for dietary control in phenylketonuria? The Lancet 2002;360(9326): ClinicalTrials.gov. A phase 3, open-label, randomized, multi-center study to assess the safety & tolerability of an induction, titration, and maintenance dose regimen of BMN 165 self administered by adults with PKU not previously treated with BMN Accessed 6 April ClinicalTrials.gov. A four-part, phase 3, randomized, double-blind, placebo- controlled, four-arm, discontinuation study to evaluate the efficacy and safety of subcutaneous injections of BMN 165 self-administered by adults with phenylketonuria (PKU). Accessed 6 April Biomarin Pharmaceutical BioMarin Phase 3 Study of Pegvaliase for Phenylketonuria (PKU) Meets Primary Endpoint of Blood Phenylalanine (Phe) Reduction (p<0.0001). 21 March investors.bmrn.com/releasedetail.cfm?releaseid= Accessed 17 May ClinicalTrials.gov. A Phase 3 Substudy to Evaluate Executive Function in Adults With Phenylketonuria Who Are Participating in the Phase 3 Study, Accessed 6 April ClinicalTrials.gov. A phase II, multi-center, open-label, dose-finding study to evaluate safety, efficacy and tolerability of subcutaneously (sc) administered ravpal-peg in patients with PKU for 24 weeks. Accessed 6 April ClinicalTrials.gov. Phase 2, open-label dose-finding study to evaluate the safety, efficacy, and tolerability of multiple subcutaneous (SC) doses of ravpal-peg in subjects with PKU. Accessed 6 April ClinicalTrials.gov. Long-term Extension of a Phase 2, Open-Label Dose-Finding Study to Evaluate the Safety, Efficacy, and Tolerability of Multiple Subcutaneous Doses of ravpal-peg in Subjects With PKU. Accessed 6 April Regnault A, Burlina A, Cunningham A et al. Development and psychometric validation of measures to assess the impact of phenylketonuria and its dietary treatment on patients and parents quality of life: the phenylketonuria quality of life (PKU-QOL) questionnaires. Orphanet Journal of Rare Diseases 2015;10:59. 10
2015 PKU Patient Survey Results. National PKU Alliance PO Box 501, Tomahawk, WI
2015 PKU Patient Survey Results National PKU Alliance PO Box 501, Tomahawk, WI 54487 www.npkua.org www.adultswithpku.org The NPKUA Patient Survey demonstrates that strict dietary therapy and treatment
More informationNew Drug Evaluation: Pegvaliase-pqpz injection, subcutaneous
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-2596
More informationHorizon Scanning Centre March Cholic acid (Orphacol) for inborn errors of primary bile acid synthesis first line SUMMARY NIHR HSC ID: 9468
Horizon Scanning Centre March 2014 Cholic acid (Orphacol) for inborn errors of primary bile acid synthesis first line SUMMARY NIHR HSC ID: 9468 This briefing is based on information available at the time
More informationAnnual Conference. 34th. The Rendezvous Hotel Skipton, Yorkshire. Welcome to. Programme Information & Abstracts
Welcome to 34th Annual Conference 2007 Programme Information & Abstracts The Rendezvous Hotel Skipton, Yorkshire The National Society for Phenylketonuria (United Kingdom) Ltd. NSPKU, PO Box 26642, London
More informationClinical Commissioning Policy: Sapropterin for Phenylketonuria (all ages) NHS England Reference: P
Clinical Commissioning Policy: Sapropterin for Phenylketonuria (all ages) NHS England Reference: 1713P 1 NHS England INFORMATION READER BOX Directorate Medical Operations and Information Specialised Commissioning
More informationESPEN Congress Madrid 2018
ESPEN Congress Madrid 2018 Inborn Errors Of Metabolism Phenylketonuria A. Macdonald (UK) Approach to Dietary Management of PKU Conflicts of interest Anita MacDonald has received research funding and honoraria
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Palynziq) Reference Number: CP.PHAR.140 Effective Date: 07.31.18 Last Review Date: 11.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of
More informationBotulinum toxin A (Dysport) for hyperhidrosis of the axillae
April 2016 Horizon Scanning Research & Intelligence Centre Botulinum toxin A (Dysport) for hyperhidrosis of the axillae LAY SUMMARY This briefing is based on information available at the time of research
More informationCLINICAL PRIORITIES ADVISORY GROUP 06 and 07 November 2018
CLINICAL PRIORITIES ADVISORY GROUP 06 and 07 November 2018 Agenda Item No 04.5 National Programme Clinical Reference Group URN Women and Children Metabolic 170103P Title Sapropterin for Phenylketonuria
More informationClinical Commissioning Policy: Sapropterin (Kuvan ) For Phenylketonuria: Use In Pregnancy. December Reference : NHSCB/E6/a
Clinical Commissioning Policy: Sapropterin (Kuvan ) For Phenylketonuria: Use In Pregnancy December 2012 Reference : NHSCB/E6/a NHS Commissioning Board Clinical Commissioning Policy: Sapropterin (Kuvan
More informationHorizon Scanning Centre November Faldaprevir with BI for chronic hepatitis C infection, genotype 1 SUMMARY NIHR HSC ID: 7688
Horizon Scanning Centre November 2012 Faldaprevir with BI 207127 for chronic hepatitis C infection, genotype 1 SUMMARY NIHR HSC ID: 7688 This briefing is based on information available at the time of research
More informationSubject: Pegvaliase-pqpz (Palynziq )
09-J3000-07 Original Effective Date: 09/15/18 Reviewed: 08/08/18 Revised: 10/15/18 Subject: Pegvaliase-pqpz (Palynziq ) THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION
More informationMerck KGaA, Darmstadt, Germany, Receives EU-Approval to Extend Kuvan Use to Children with PKU Below 4 Years of Age
Your Contact News Release Gangolf Schrimpf +49 6151 72-9591 Investor Relations +49 6151 72-3321 July 20, 2015 Merck KGaA, Darmstadt, Germany, Receives EU-Approval to Extend Kuvan Use to Children with PKU
More informationHorizon Scanning Centre November Enobosarm (Ostarine) for cachexia in patients with advanced non-small cell lung cancer first line
Horizon Scanning Centre November 2012 Enobosarm (Ostarine) for cachexia in patients with advanced non-small cell lung cancer first line SUMMARY NIHR HSC ID: 5206 This briefing is based on information available
More informationPKU, KUVAN, and You PKU treatment and support for adults and young adults
PKU, KUVAN, and You PKU treatment and support for adults and young adults An educational brochure brought to you by BioMarin Pharmaceutical Inc. Phe control it s a lifelong goal! Most young people with
More information1 Cognitive, Psychological and Behavioral Assessment Based Evidence
1 Cognitive, Psychological and Behavioral Assessment Based Evidence Preface Current medical evidence has led experts on PKU to suspect that current therapy for PKU may leave individuals with an increased
More informationNot intended for UK based media. Merck Announces Detailed 26-Week Results from Phase IIIb Study with Kuvan in children with PKU below 4 years of age
Your Contact News Release Bettina Frank Phone +49 6151 72-4660 Not intended for UK based media Merck Announces Detailed 26-Week Results from Phase IIIb Study with Kuvan in children with PKU below 4 years
More informationRevision Log. See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Kuvan) Reference Number: CP. PHAR.43 Effective Date: 02.01.10 Last Review Date: 02.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationSetmelanotide for pro-opiomelanocortin deficiency obesity
NIHR Innovation Observatory Evidence Briefing: September 2017 Setmelanotide for pro-opiomelanocortin deficiency obesity NIHRIO (HSRIC) ID: 8496 NICE ID: 9505 LAY SUMMARY Body fat and food intake are regulated
More informationPanel: Report of Scientific Advisory Board Research Advancements July 30, 8:15am-9:15am
Panel: Report of Scientific Advisory Board Research Advancements July 30, 8:15am-9:15am Dr. Cary Harding National PKU Alliance (NPKUA) July 28-31, 2016, Indianapolis, IN Disclosures Cary Harding has received
More informationInsulin degludec/insulin aspart (DegludecPlus) for type 1 diabetes
Insulin degludec/insulin aspart (DegludecPlus) for type 1 diabetes This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationLacosamide (Vimpat) for partial-onset epilepsy monotherapy. December 2011
Lacosamide (Vimpat) for partial-onset epilepsy monotherapy This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a
More informationRilonacept for cryopyrin associated periodic syndromes
Rilonacept for cryopyrin associated periodic syndromes August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationCommittee Approval Date: August 15, 2014 Next Review Date: September 2015
Medication Policy Manual Policy No: dru152 Topic: Kuvan, sapropterin Date of Origin: March 18, 2008 Committee Approval Date: August 15, 2014 Next Review Date: September 2015 Effective Date: October 1,
More informationNational Horizon Scanning Centre. Ampligen for chronic fatigue syndrome. December 2007
Ampligen for chronic fatigue syndrome December 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive
More informationHorizon Scanning Centre November Spheroids of human autologous matrix-associated chondrocytes (Chondrosphere) for articular cartilage defects
Horizon Scanning Centre November 2014 Spheroids of human autologous matrix-associated chondrocytes (Chondrosphere) for articular cartilage defects SUMMARY NIHR HSC ID: 8515 This briefing is based on information
More informationHorizon Scanning Centre November Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330
Horizon Scanning Centre November 2012 Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330 Secukinumab is a high-affinity fully human monoclonal antibody that antagonises
More informationSummary 1. Comparative effectiveness of sapropterin dihydrochloride
Cost-effectiveness of sapropterin dihydrochloride (Kuvan ) for the treatment of hyperphenylalaninaemia (HPA) in adults and paediatric patients of all ages with phenylketonuria (PKU) who have been shown
More informationB-cell lymphoma vaccine (BiovaxID) for follicular non-hodgkin s lymphoma
B-cell lymphoma vaccine (BiovaxID) for follicular non-hodgkin s lymphoma May 2010 This technology summary is based on information available at the time of research and a limited literature search. It is
More informationHorizon Scanning Centre March Denosumab for glucocorticoidinduced SUMMARY NIHR HSC ID: 6329
Horizon Scanning Centre March 2014 Denosumab for glucocorticoidinduced osteoporosis SUMMARY NIHR HSC ID: 6329 This briefing is based on information available at the time of research and a limited literature
More informationPKU PKU. Phenylketonuria TEMPLE. Information for families following Information for families after a positive newborn screening
PKU Phenylketonuria PKU Information for families following newborn a positive screening newborn screening Information for families after a positive newborn screening Information for families after a positive
More informationMolecular Genetics and Metabolism
Molecular Genetics and Metabolism 101 (2010) 110 114 Contents lists available at ScienceDirect Molecular Genetics and Metabolism journal homepage: www.elsevier.com/locate/ymgme Sapropterin therapy increases
More informationBioMarin Pharmaceutical Inc. Conference Call to Discuss Approval of
BioMarin Pharmaceutical Inc. Conference Call to Discuss Approval of For adult patients with PKU who have uncontrolled blood phenylalanine (Phe) concentrations > 600 µmol/l on existing management May 24,
More informationInsulin glulisine (Apidra) for type 1 diabetes mellitus in adolescents and children
Insulin glulisine (Apidra) for type 1 diabetes mellitus in adolescents and children December 2008 This technology summary is based on information available at the time of research and a limited literature
More informationEverolimus (Votubia) for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis first line or post surgery
Everolimus (Votubia) for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis first line or post surgery April 2011 This technology summary is based on information
More informationCertolizumab pegol (Cimzia) for psoriatic arthritis second line
Certolizumab pegol (Cimzia) for psoriatic arthritis second line This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationRiociguat for chronic thromboembolic pulmonary hypertension
Riociguat for chronic thromboembolic pulmonary hypertension This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a
More informationCilengitide (Impetreve) for glioblastoma multiforme. February 2012
Cilengitide (Impetreve) for glioblastoma multiforme February 2012 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationCertolizumab pegol (Cimzia) for chronic plaque psoriasis in adults
NIHR Innovation Observatory Evidence Briefing: April 2017 Certolizumab pegol (Cimzia) for chronic plaque psoriasis in adults NIHRIO (HSRIC) ID: 2406 NICE ID: 9112 LAY SUMMARY Plaque psoriasis is the most
More informationAR101 peanut allergy immunotherapy for adult and paediatric patients
AR101 peanut allergy immunotherapy for adult and paediatric patients NIHRIO (HSRIC) ID: 11815 NIHR Innovation Observatory Evidence Briefing: May 2017 NICE ID: 8773 LAY SUMMARY Food allergy occurs when
More informationKTE-C19 for relapsed or refractory mantle cell lymphoma
NIHR Innovation Observatory Evidence Briefing: July 2017 KTE-C19 for relapsed or refractory mantle cell lymphoma NIHRIO (HSRIC) ID: 11846 NICE ID: 9122 LAY SUMMARY Mantle cell lymphoma is an uncommon type
More informationNational Horizon Scanning Centre. Mannitol dry powder for inhalation (Bronchitol) for cystic fibrosis. April 2008
Mannitol dry powder for inhalation (Bronchitol) for cystic fibrosis April 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationLiraglutide (Victoza) in combination with basal insulin for type 2 diabetes
Liraglutide (Victoza) in combination with basal insulin for type 2 diabetes May 2011 This technology summary is based on information available at the time of research and a limited literature search. It
More informationrhngf for neurotrophic keratitis first line
September 2015 Horizon Scanning Research & Intelligence Centre rhngf for neurotrophic keratitis first line LAY SUMMARY This briefing is based on information available at the time of research and a limited
More informationCabozantinib for medullary thyroid cancer. February 2012
Cabozantinib for medullary thyroid cancer February 2012 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive
More informationChapter 1: What is PKU?
Chapter 1: What is PKU? A Parent's Perspective "If our child with PKU had been our first instead of our third, or if we had wanted more children after we had her, we would have done so, even knowing the
More informationNational Horizon Scanning Centre. Methylnaltrexone (MOA-728) for postoperative ileus. April 2008
(MOA-728) for postoperative ileus April 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive statement
More informationNEOD001 for amyloid light-chain (AL) amyloidosis
NIHR Innovation Observatory Evidence Briefing: October 2017 NEOD001 for amyloid light-chain (AL) amyloidosis NIHRIO (HSRIC) ID: 10617 NICE ID: 8803 LAY SUMMARY Amyloid light-chain (AL) amyloidosis is caused
More informationNational Horizon Scanning Centre. Pregabalin (Lyrica) for fibromyalgia. September 2007
Pregabalin (Lyrica) for fibromyalgia September 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive
More informationCertolizumab pegol (Cimzia) for the treatment of ankylosing spondylitis second or third line
Certolizumab pegol (Cimzia) for the treatment of ankylosing spondylitis second or third line August 2011 This technology summary is based on information available at the time of research and a limited
More informationNational Horizon Scanning Centre. Aflibercept (VEGF Trap) for advanced chemo-refractory epithelial ovarian cancer. December 2007
Aflibercept (VEGF Trap) for advanced chemo-refractory epithelial ovarian cancer December 2007 This technology summary is based on information available at the time of research and a limited literature
More informationUstekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs)
Ustekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs) January 2010 This technology summary is based on information available at the time of research
More informationLenti D for adrenoleukodystrophy in boys NIHRIO (HSRIC) ID: 7992 NICE ID: 8732
NIHR Innovation Observatory Evidence Briefing: May 2017 Lenti D for adrenoleukodystrophy in boys NIHRIO (HSRIC) ID: 7992 NICE ID: 8732 LAY SUMMARY Adrenoleukodystrophy (ALD), otherwise known as Lorenzo
More informationClinical Commissioning Policy Proposition: Everolimus for subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex
Clinical Commissioning Policy Proposition: Everolimus for subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex Reference: NHS England E09X04/01 Information Reader Box (IRB)
More informationAtomoxetine (First known as Tomoxetine) (Adopted by the CCG until review and further notice)
New Medicine Report Document Status Atomoxetine (First known as Tomoxetine) (Adopted by the CCG until review and further notice) Post Suffolk D&TC Traffic Light Decision RED Date of Last Revision 12.07.04
More informationHorizon Scanning Technology Summary. Cyanocobalamin nasal spray (Nascobal) for vitamin B12 deficiency. National Horizon Scanning Centre.
Horizon Scanning Technology Summary National Horizon Scanning Centre Cyanocobalamin nasal spray (Nascobal) for vitamin B12 deficiency April 2007 This technology summary is based on information available
More informationNational Horizon Scanning Centre. Vandetanib (Zactima) for locally advanced or metastatic medullary thyroid cancer. December 2007
Vandetanib (Zactima) for locally advanced or metastatic medullary thyroid cancer December 2007 This technology summary is based on information available at the time of research and a limited literature
More information2. SYNOPSIS Name of Sponsor/Company:
in patients with refractory partial seizures 14 Jun 2007 2. SYNOPSIS TITLE OF STUDY: Efficacy and safety of BIA 2-093 as adjunctive therapy for refractory partial seizures in a double-blind, randomized,
More informationHorizon Scanning Technology Briefing. Sutent (Sunitinib) for first-line and adjuvant treatment of renal cell carcinoma
Horizon Scanning Technology Briefing National Horizon Scanning Centre Sutent (Sunitinib) for first-line and adjuvant treatment of renal cell carcinoma August 2006: Updated October 2006 This technology
More informationAnnual Conference. 33rd. The Hinckley Island Hotel. Welcome to. Programme Information & Abstracts
Welcome to 33rd Annual Conference 2006 Programme Information & Abstracts The Hinckley Island Hotel The National Society for Phenylketonuria (United Kingdom) Ltd. NSPKU, PO Box 26642, London N14 4ZF Contents
More informationPHENYLKETONURIA. Debbie Galo
PHENYLKETONURIA Debbie Galo What it is PKU? 1934 Metabolic disorder (chromosome 12) Autosomal recessive Deficiency of enzyme Phenylalanine Hydroxylase (PAH) Cannot convert phenylalanine to tyrosine More
More informationPKU TEMPLE. Tools Enabling Metabolic Parents LEarning ADAPTED AND ENDORSED BY ASIEM FOR USE IN ANZ DESIGNED AND ADAPTED BY THE DIETITIANS GROUP
TEMPLE Tools Enabling Metabolic Parents LEarning ADAPTED AND ENDORSED BY ASIEM FOR USE IN ANZ Australasian Society for Inborn Errors of Metabolism DESIGNED AND ADAPTED BY THE DIETITIANS GROUP PKU British
More informationGuideline scope Neonatal parenteral nutrition
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Guideline scope Neonatal parenteral nutrition The Department of Health in England has asked NICE to develop a new guideline on parenteral nutrition in
More informationOlesoxime for amyotrophic lateral sclerosis first line
Olesoxime for amyotrophic lateral sclerosis first line May 2011 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationNational Horizon Scanning Centre. Mepolizumab (Bosatria) for hypereosinophilic syndrome first line in combination with corticosteroids.
Mepolizumab (Bosatria) for hypereosinophilic syndrome first line in combination with corticosteroids May 2008 This technology summary is based on information available at the time of research and a limited
More informationScottish Medicines Consortium
Scottish Medicines Consortium levetiracetam, 250, 500, 750 and 1000mg tablets and levetiracetam oral solution 100mg/ml (Keppra ) No. (394/07) UCB Pharma Limited 10 August 2007 The Scottish Medicines Consortium
More informationNEUROCOGNITIVE, OUTCOMES IN PKU: IT S TIME TO RAISE THE BAR
NEUROCOGNITIVE, OUTCOMES IN : IT S TIME TO RAISE THE BAR KEY POINTS 1. High Phenylalanine (Phe) levels harm the brain.. Traditional therapies do not completely protect individuals with. 3. New approaches
More informationBoston Children s Hospital Transition Toolkit
Boston Children s Hospital Transition Toolkit Welcome to the Boston Children s Hospital Transition Toolkit! As a teenager getting ready for adulthood, or as a young adult, you can begin to take control
More informationVoxelotor for sickle cell disease
NIHR Innovation Observatory Evidence Briefing: November 2017 Voxelotor for sickle cell disease NIHRIO (HSRIC) ID: 10748 NICE ID: 9700 LAY SUMMARY Sickle cell disease (SCD) describes a group of inherited
More informationASD and ADHD Pathway. Pride in our children s, young people s and families s e r v i c e s A member of Cambridge University Health Partners
ASD and ADHD Pathway 30-11-2017 Pride in our care Pride in our children s, young people s and families s e r v i c e s A member of Cambridge University Health Partners ADHD NICE Guidance: Organisation
More informationReturning. Diet P K U
Returning to Diet P K U RETURNING TO A LOW PHENYLALANINE DIET PHENYLKETONURIA What is it? Phenylketonuria (PKU) is a condition inherited from both parents. It was diagnosed when you were about a week old
More informationRelationship between socioeconomic status and quality of life of children with phenylketonuria
Relationship between socioeconomic status and quality of life of children with phenylketonuria Lacramioara Aurelia Brinduse, MD, PhD Prof. Dana Galieta Minca, MD, PhD Michaela Iuliana Nanu MD, PhD Phenylketonuria
More informationThe National Society for Phenylketonuria (United Kingdom) Ltd. The Child with PKU. Brenda Clark Professor Forester Cockburn Dr Linda Tyfield
The National Society for Phenylketonuria (United Kingdom) Ltd. The Child with PKU Brenda Clark Professor Forester Cockburn Dr Linda Tyfield Revised by Dr Andrew Morris Front cover illustration kindly provided
More informationAppendix 4I - Melatonin Guidance for the treatment of sleep-wake cycle disorders in children
Appendix 4I - Melatonin Guidance for the treatment of sleep-wake cycle disorders in children Background Sleep disturbance in children with neurological or behavioural disorders is common and can be a major
More informationBehavioural Disorders
Behavioural Disorders BEH Hyperkinetic disorder / attention deficit hyperactivity disorder (ADHD) Behavioural disorders is an umbrella term that includes more specific disorders, such as hyperkinetic disorder
More informationNational Horizon Scanning Centre. Decitabine (Dacogen) for myelodysplastic syndrome. April 2008
Decitabine (Dacogen) for myelodysplastic syndrome April 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be
More informationHorizon Scanning Technology Summary. Abatacept (Orencia) for juvenile idiopathic arthritis. National Horizon Scanning Centre.
Horizon Scanning Technology Summary National Horizon Scanning Centre Abatacept (Orencia) for juvenile idiopathic arthritis June 2007 This technology summary is based on information available at the time
More informationNeuren s trofinetide successful in proof of concept Phase 2 clinical trial in Fragile X syndrome
Neuren (NEU) - ASX Announcement 7 December 2015 Neuren s trofinetide successful in proof of concept Phase 2 clinical trial in Fragile X syndrome Highlights: Positive top-line results provide a strong rationale
More informationAdult PKU. Important Information for You. Mead Johnson Metabolics
This booklet is intended by Mead Johnson to be provided to you by your healthcare professional as part of his or her care plan in the dietary management of PKU. Your healthcare professional is your primary
More informationApixaban for stroke prevention in atrial fibrillation. August 2010
Apixaban for stroke prevention in atrial fibrillation August 2010 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationErlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy
Erlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy September 2008 This technology summary is based on information available at the time of research and a
More informationAbatacept (Orencia) for active rheumatoid arthritis. August 2009
Abatacept (Orencia) for active rheumatoid arthritis August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationOtamixaban for non-st-segment elevation acute coronary syndrome
Otamixaban for non-st-segment elevation acute coronary syndrome September 2011 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationPasireotide Long-Acting Repeatable (Signifor) for acromegaly first and second line
Pasireotide Long-Acting Repeatable (Signifor) for acromegaly first and second line December 2010 This technology summary is based on information available at the time of research and a limited literature
More informationTEMPLE. Tools Enabling Metabolic Parents LEarning ADAPTED BY THE DIETITIANS GROUP. British Inherited Metabolic Diseases Group
TEMPLE Tools Enabling Metabolic Parents LEarning ADAPTED BY THE DIETITIANS GROUP British Inherited Metabolic Diseases Group BASED ON THE ORIGINAL TEMPLE WRITTEN BY BURGARD AND WENDEL PKU Information for
More informationNATIONAL INSTITUTE FOR CLINICAL EXCELLENCE SCOPE. Nutrition support in adults: oral supplements, enteral and parenteral feeding.
NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE 1 Guideline title SCOPE Nutrition support in adults: oral supplements, enteral and parenteral feeding. 1.1 Short title Nutrition support 2 Background a) The National
More informationHorizon Scanning Technology Summary. Adalimumab (Humira) for juvenile idiopathic arthritis. National Horizon Scanning Centre.
Horizon Scanning Technology Summary National Horizon Scanning Centre Adalimumab (Humira) for juvenile idiopathic arthritis June 2007 This technology summary is based on information available at the time
More informationSAGE-547 for super-refractory status epilepticus
NIHR Innovation Observatory Evidence Briefing: April 2017 SAGE-547 for super-refractory status epilepticus NIHRIO (HSRIC) ID: 10866 NICE ID: 8456 Status epilepticus is a single epileptic seizure lasting
More informationErtugliflozin for type 2 diabetes mellitus
October 2016 Horizon Scanning Research & Intelligence Centre Ertugliflozin for type 2 diabetes mellitus NIHR HSRIC ID: 7712; 11910; 12223; 12238 Lay summary Ertugliflozin is a new drug to treat type 2
More informationAn Update on BioMarin Clinical Research and Studies in the PKU Community
An Update on BioMarin Clinical Research and Studies in the PKU Community Barbara Burton, MD, Professor of Pediatrics, Northwestern University Feinberg School of Medicine, Director of PKU Clinic, Children
More informationDietary Treatment of the Untreated Adult PKU
Dietary Treatment of the Untreated Adult PKU Bryan Pearce St. Ives Bay with Cargo Ship 1995 Written by Rosemary Hoskin, SRD Senior Dietitian, Horizon NHS Trust, Harperbury Radlett, Herts in conjunction
More informationNational Horizon Scanning Centre. Dronedarone (Multaq) for atrial fibrillation and atrial flutter. December 2007
Dronedarone (Multaq) for atrial fibrillation and atrial flutter December 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Kuvan 100 mg soluble tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each soluble tablet contains 100 mg of sapropterin
More informationPKU, KUVAN, and Your Child Making smart choices for PKU treatment
PKU, KUVAN, and Your Child Making smart choices for PKU treatment An educational brochure brought to you by BioMarin Pharmaceutical Inc. + = Low Low- diet Indication KUVAN (sapropterin dihydrochloride)
More informationTicagrelor (Brilique) for peripheral arterial disease
July 2016 Horizon Scanning Research & Intelligence Centre Ticagrelor (Brilique) for peripheral arterial disease LAY SUMMARY This briefing is based on information available at the time of research and a
More informationNational Horizon Scanning Centre. Azacitidine (Vidaza) for myelodysplastic syndrome. September 2007
Azacitidine (Vidaza) for myelodysplastic syndrome September 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationNational Horizon Scanning Centre. Ipilimumab (MDX-010) for unresectable stage III or IV metastatic melanoma - first or second line treatment
Ipilimumab (MDX-010) for unresectable stage III or IV metastatic melanoma - first or second line treatment April 2008 This technology summary is based on information available at the time of research and
More informationHorizon Scanning Technology Summary. Tenofovir disoproxil fumarate for hepatitis B. National Horizon Scanning Centre. April 2007
Horizon Scanning Technology Summary National Horizon Scanning Centre Tenofovir disoproxil fumarate for hepatitis B April 2007 This technology summary is based on information available at the time of research
More information